中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

33 records (took 0.031 seconds)

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    21.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10323093B2

    公开(公告)日：2019-06-18

    申请号：US16230657

    申请日：2018-12-21

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    22.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10323092B2

    公开(公告)日：2019-06-18

    申请号：US16006493

    申请日：2018-06-12

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    23.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10308714B2

    公开(公告)日：2019-06-04

    申请号：US16024340

    申请日：2018-06-29

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    25.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10266594B1

    公开(公告)日：2019-04-23

    申请号：US16213954

    申请日：2018-12-07

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  G01N33/574 ,  C07K16/18 ,  A61K39/395 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    27.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10316091B2

    公开(公告)日：2019-06-11

    申请号：US16024333

    申请日：2018-06-29

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
    29.
    发明授权
    Cancer immunotherapy by disrupting PD-1/PD-L1 signaling 有权

    公开(公告)号：US10266595B2

    公开(公告)日：2019-04-23

    申请号：US16213960

    申请日：2018-12-07

    Applicant: Bristol-Myers Squibb Company

    Inventor： John P. Cogswell ,  Stacie M. Goldberg ,  Ashok K. Gupta ,  Maria Jure-Kunkel ,  Xi-Tao Wang ,  Jon M. Wigginton

    IPC: C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00

    Abstract: The disclosure provides a method for immunotherapy of a subject afflicted with cancer, comprises administering to the subject a composition comprising a therapeutically effective amount of an antibody that inhibits signaling from the PD-1/PD-L1 signaling pathway. This disclosure also provides a method for immunotherapy of a subject afflicted with cancer comprising selecting a subject that is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the subject that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering a therapeutically effective amount of an anti-PD-1 antibody to the selected subject. The invention additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.

Patent Agency Ranking